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Abstract
Background: Plasmodium falciparum malaria remains a major health problem in Africa. The mechanisms of
pathogenesis are not fully understood. Transcriptomic studies may provide new insights into molecular pathways
involved in the severe form of the disease.
Methods: Blood transcriptional levels were assessed in patients with cerebral malaria, non-cerebral malaria, or mild
malaria by using microarray technology to look for gene expression profiles associated with clinical status. Multi-way
ANOVA was used to extract differentially expressed genes. Network and pathways analyses were used to detect
enrichment for biological pathways.
Results: We identified a set of 443 genes that were differentially expressed in the three patient groups after applying a
false discovery rate of 10%. Since the cerebral patients displayed a particular transcriptional pattern, we focused our
analysis on the differences between cerebral malaria patients and mild malaria patients. We further found 842
differentially expressed genes after applying a false discovery rate of 10%. Unsupervised hierarchical clustering of
cerebral malaria-informative genes led to clustering of the cerebral malaria patients. The support vector machine
method allowed us to correctly classify five out of six cerebral malaria patients and six of six mild malaria patients.
Furthermore, the products of the differentially expressed genes were mapped onto a human protein-protein network.
This led to the identification of the proteins with the highest number of interactions, including GSK3B, RELA, and APP.
The enrichment analysis of the gene functional annotation indicates that genes involved in immune signalling
pathways play a role in the occurrence of cerebral malaria. These include BCR-, TCR-, TLR-, cytokine-, FcεRI-, and FCGR-
signalling pathways and natural killer cell cytotoxicity pathways, which are involved in the activation of immune cells.
In addition, our results revealed an enrichment of genes involved in Alzheimer’s disease.
Conclusions: In the present study, we examine a set of genes whose expression differed in cerebral malaria patients
and mild malaria patients. Moreover, our results provide new insights into the potential effect of the dysregulation of
gene expression in immune pathways. Host genetic variation may partly explain such alteration of gene expression.
Further studies are required to investigate this in African populations.
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Background
Plasmodium falciparum malaria remains a leading cause
of mortality and morbidity in tropical countries. It encom-
passes a broad range of clinical phenotypes, including mild
and severe forms of the disease. Cerebral malaria (CM),
severe anaemia, and respiratory distress are the main syn-
dromes of severe malaria (SM). According to a World
Health Organization (WHO) report, major complications
account for 429,000 deaths annually [1]. In particular, CM
is defined as a diffuse encephalopathy with seizures and
impaired consciousness, and its case fatality rate has not
changed over decades [2]. Patients are treated with anti-
malarial drugs, and it is thought that adjunctive therapies,
such as anti-inflammatory, vasculo- and neuro-protective
therapies, and new biomarkers for early diagnosis are
needed. The outcome of infection depends on numerous
factors, such as parasite virulence, host age, host immune
status, and host and parasite genetics. Genome-wide asso-
ciation studies have been conducted in African popula-
tions to identify biomarkers associated with SM and to
decipher the molecular basis of the pathogenesis. They
have yielded, however, very few significant association
results [3–5], likely due to a poor knowledge of the linkage
disequilibrium patterns in African populations [6], and
thus, to a lack of relevant tagSNPs for GWAS in Africa.
Whole genome sequencing of individuals living in differ-
ent African areas should overcome this limitation in the
future. The assessment of genome-wide levels of exp-
ression is an alternative approach to identify relevant
candidate genes and molecular pathways involved in
pathogenesis.
In this way, transcriptional studies have been carried
out in a CM mouse model, and have led to the discovery
of genes, whose up- or down-regulation in several tis-
sues was associated with CM, and which were involved
in specific pathways, such as metabolic energy pathways,
inflammatory response, antigen presentation, and T cell
receptor signalling and pathways related to neurogenesis
and neurodegenerative disorders [7, 8]. In humans, tran-
scriptional profiling has been used very recently to
search for molecular markers associated with malaria.
Transcriptional studies have been carried out either in
an in vitro model of CM or on blood cells taken from
patients with either SM or mild malaria (MM). The
in vitro model study has shown that TNF, platelets, and
infected red blood cells significantly influence the
expression of genes in endothelial cells [9]. Ex vivo stud-
ies that compared gene expression levels in SM patients
and those in MM patients identified several host genes
whose expression levels were associated with SM in Mali
and Malawi [10–12], pointed out the involvement of
immune pathways, such as interferon pathways and
Toll-like receptor signalling [11, 12], and revealed genes
involved in neurodegenerative disorders [13]. Moreover,
a transcriptional study that investigated gene expression
levels in blood taken from CM patients with and without
malaria retinopathy revealed that cell adhesion and
cytokine pathways were positively associated with mal-
aria retinopathy [10]. In addition, ex vivo parasite tran-
scriptional studies led to the identification of up- or
down-regulated parasite genes associated with high para-
sitaemia or malaria retinopathy, and involved in cell ad-
hesion, glycolysis or DNA replication [14, 15].
For the present study, we conducted a blood transcrip-
tional analysis in Senegalese patients with CM, severe
non-cerebral malaria (NCM), or MM in order to identify
human genes whose expression levels are associated with
the severity of the disease. We identified gene clusters
that discriminated between CM and MM patients, and
provided evidence of pathways associated with CM.
Methods
Patients and samples
Senegalese patients with clinical malaria were enrolled at
the Principal Hospital of Dakar, the National Hospital
Centre of Pikine, and the Regional Hospital of Tamba-
counda. Prior to enrolment, written or verbal informa-
tion on the study was given in their native language, and
informed consent was obtained from the participants or
their relatives. At the day of admission, biological data
including P. falciparum parasitaemia, haematological
and biochemical characteristics were determined by hos-
pitals’ medical laboratories and recorded, as previously
described [16]. For all patients, the presence of P. falcip-
arum infection was determined by an immunoassay
detecting PfHRP2 (Standard diagnostics-Abott-Inc, Chi-
cago, Illinois, USA). For 12 out of 16 patients P. falcip-
arum parasitaemia was determined by microscopic
examination of thin and thick blood smears, prior to
anti-malarial treatment. The protocols were approved by
the investigator’s institutions, the National Ethical Com-
mittee and the Ministry of Health of Senegal. The clin-
ical cases were defined according to the WHO criteria
[17]. MM cases were defined on the basis of fever with
P. falciparum parasitaemia of < 25,000 parasites/μl of
blood, with no evidence of impaired consciousness, con-
vulsions, severe anaemia, hypoglycaemia, respiratory dis-
tress, or hypoxia. The presence of a deep coma, lack of
purposeful response, lack of response to a painful stimu-
lus by Glasgow score < 9, a diagnosed P. falciparum in-
fection, without other clinically cause of impaired
consciousness, such as hypoglycemia, meningitis, and
encephalitis according to WHO criteria qualified the pa-
tients as having CM. NCM cases were defined on the
basis of isolated symptoms of SM such as severe
anaemia, hypoglycaemia, respiratory distress, or hypoxia,
and the absence of neurological symptoms such as
impaired consciousness, convulsions and long-term
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neurological deficits. Peripheral blood was taken by
venipuncture on hospital admission. Blood samples (ap-
proximately 5 ml) were diluted and peripheral blood
mononuclear cells (PBMC) were collected by Ficoll-
Histopaque-1077 (Sigma-Aldrich, Saint-Quentin Falla-
vier) density-gradient centrifugation for RNA. After
washing twice with PBS, PBMCs were stored at − 80 °C.
Microarray processing (RNA extraction, amplification, and
hybridization)
RiboNucleic Acid (RNA) extraction was carried out
using TRIzol (Gibco, Invitrogen Corporation), according
to the manufacturer’s instructions. The quantification of
RNA was performed using the NanoDrop ND-1000 UV-
Vis spectrophotometer (Thermo Fisher Scientific, Ill-
kirch, France), and the quality of the RNA samples was
analysed with the Bioanalyzer 2100 (Agilent Technolo-
gies®, Massy, France) and Agilent chips (RNA Nano
Chip®). Samples with an RNA Integrity Number (RIN) >
8 were retained. Samples and microarrays were next
processed according to Agilent’s recommendations. In
brief, total RNA was reverse-transcribed with the Affini-
tyScript RT enzyme and cDNA was transcribed in vitro.
cRNA was further obtained using T7 RNA polymerase
and labelled using Cy3-CTP, before fragmentation and
hybridization (600 ng per sample for 17 h at 65 °C) to a
SurePrint G3 Human GE 8x60k microarray. After wash-
ing, the microarrays were scanned with the SureScan
Agilent Microarray Scanner.
Microarray analysis
The quantification of signals was performed with Agi-
lent’s Feature Extraction Software. From the raw data,
data filtering, normalization and data backup were per-
formed using the R statistical software package. The
quantile method was used to normalize the data. A filter
was applied on the raw data to delete controls, and then
a second filter was applied to delete probes that showed
a signal under the background; finally, 26,372 probes
were further analyzed. Data were deposited in the GEO
database under GSE116306. Statistical analysis was per-
formed using the TIGR MeV (MultiExperiment Viewer)
v4.1 software (http://mev.tm4.org/#/welcome) and the
GeneANOVA program [18, 19]. Figure 1 shows the
schematic outline of statistical analyses. Welch t-test was
used to compare CM patient gene expression levels with
those of MM patients. A multi-way ANOVA was used
to take into account the influence of covariates, such as
age, gender, and leukocyte counts. The ANOVA model
gives an estimation of the contribution of each factor in
the total variation of the whole data set. Furthermore, a
local ANOVA allows the determination of each contri-
bution for each gene; it gives an estimation of the vari-
ation due to the factor studied, and the significance of
the estimate. An FDR of 10% was applied to correct for
multiple tests. An unsupervised hierarchical clustering of
the samples was carried out on the basis of the expres-
sion of the selected genes. A ‘1-out-iterative cross-
validation’ testing procedure was used to ascertain the
accuracy of the classification.
Fig. 1 Schematic outline of statistical analyses. Blood gene expression levels in MM, CM, and NCM patients were compared (a), and blood gene
expression levels in MM patients were compared to that in CM patients (b). Analyses of variance were carried out to identify significant probes
and genes. Enrichment analyses were performed to determine molecular pathways potentially involved in malaria pathogenesis. An FDR of 10%
was applied to correct for multiple tests
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Table 1 Characteristics of patients
Cerebral malaria (N = 6) Non cerebral malaria (N = 4) Mild malaria (N = 6)
Gender
Female 3 1 3
Male 3 3 3
Survival
Dead 2 0 0
Alive 4 4 4
Age (years)
Median (minimum-maximum) 21 (1–72) 3 (2–12) 3.5 (1–40)
Haemoglobin (g/dL)
Median (minimum-maximum) 9.2 (7.9–15.1) 8.1 (3.2–14.1) 8.1 (3.7–12.6)
Red blood cells (×106/μL)
Median
(minimum-maximum)
3.7 (2.8–8.4) 2.76 (1.36–3.9) 4.0 (1.6–4.7)
Leucocytes (× 103/μL)
Median (minimum-maximum) 13.5 (6.7–19.4) 10.1 (3.9–45.0) 15.0 (5.8–38.8)
Platelets (×103/μL)
Median (minimum-maximum) 53.5 (25.0–155.0) 287.0 (40.3–456.0) 309.0 (92.0–474.0)
Fig. 2 Gene expression profiles in blood samples from cerebral malaria (CM), severe non-cerebral malaria (NCM), and mild malaria (MM) patients.
Red and green indicate expression levels above and below the median, respectively. A one-way ANOVA led to the selection of differentially
expressed genes in the three patient groups, and those genes were used to carry out a hierarchical clustering (a). A Welch t-test led to the
selection of 14 genes, and a hierarchical clustering was performed on this basis (b). Each column represents a patient, whereas each line
represents a probe. Selected probes and genes had a nominal P value lower than 0.001. Genes that were down- and up-regulated in CM patients
are shown in cluster A and cluster B, respectively. The list of those genes is shown in Additional file 1: Table S1
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Functional enrichment analysis
The gene annotation of the selected genes was per-
formed using Genomic Regions Enrichment of Anno-
tation Tool (GREAT), Enrichr, and NetworkAnalyst
[20–22]. Those programs, which allow a biological in-
terpretation of gene clusters on the basis of Molecular
Signatures Database, Kyoto Encyclopaedia of Genes
and Genomes (KEGG) pathways, Reactome pathways,
and protein-protein interactions, were used to assess
the functional enrichment for differentially expressed
genes. Fisher exact and hypergeometric tests were
used, whereas an FDR of 10% was applied to correct
for multiple tests.
The selected genes were used to construct and
visualize the network using NetworkAnalyst [21]. The
underlying protein-protein interactions were obtained
from InnateDB [23]. The minimum interaction network
option was used, and a first-order interaction network
that was composed only of the seed nodes and their dir-
ect interactors was created; it was further trimmed to
keep only the nodes that connected the seed nodes. The
degree centrality and the betweenness centrality were
also calculated.
Quantitative real time PCR
The RT-QPCR was performed on all samples from CM
and MM patients. Eight genes (ZBTB43, TICAM1,
PI4K2A, HIC2, ZNHIT3, NFE2, NCR3 and IL18R1) were
selected for validation experiments. RT-PCR was per-
formed for each sample from the total RNA with the
VILO SuperScript kit (Invitrogen, Carlsbad, California)
based on the protocol provided. In summary, 500 ng of
total RNA was mixed with 4 μl of the SuperScrip VILO
MasterMix supplied in the kit and 5 pmol of primers in
a total volume of 20 μl DEPC-treated water. The samples
were vortexed and incubated, respectively, at 25 °C, 10
min and 42 °C, 1 h before the reaction was complete at
85 °C, 5 min. The qPCR testing was performed in 96-
well plates with the product of the RT-PCR. Briefly, 2 μl
of each sample, diluted to 1/10, was added to a solution
containing 5 pmol / μl of each foward and reverse pri-
mer (Eurofins Genomics, Ebersberg), 12.5 μL of SYBR
Green Master Mix (Thermo Fisher Scientific) and 8.5 μL
of RNase / DNase free water. The experiment was car-
ried out with the QuantStudio 6 Flex Real-Time PCR
System apparatus using the following steps: pre-
incubation cycle at 95 °C during 10 min; 40 amplification
cycles at 95 °C during 15 s, and 60 °C during 60 s; 1 melt-
ing cycle at 95 °C during 15 s, 60 °C during 1 min, and
95 °C during 15 s. Gene expression levels were then cal-
culated after normalizing the measurements on the
GAPDH level and a reference sample.
Results
Patients
Blood samples taken from 16 patients were investigated: 6
from CM patients, 4 from severe NCM patients, and 6
from MM patients. Table 1 shows the patient characteris-
tics in the patient groups. There was no significant differ-
ence between the groups for age (P = 0.15), haemoglobin
concentration (P = 0.55), red blood cell count (P = 0.87),
and leucocyte count (P = 0.81) on the basis of a Kruskal-
Wallis test. In contrast, there was a difference for platelet
count (P = 0.018).
Gene expression analysis
We performed a one-way ANOVA to identify genes
whose expression may differ in MM, NCM, and CM pa-
tients. Thirty-six probes corresponding to 28 genes
showed a difference with a nominal P value threshold of
0.001 (Additional file 1: Table S1), whereas there was no
significant difference after applying a false discovery rate
(FDR) of 10%. Since the CM patients appeared to show
a particular pattern, we carried out a Welch t-test to
compare the level of gene expression in CM patients
with the level in MM patients. We identified 14 differen-
tially expressed genes on the basis of nominal P values
lower than 0.001 (Additional file 1: Table S1). However,
Table 2 Multi-way ANOVA of gene expression levels in blood
samples from MM, NCM, and CM patients
Factor Sum of square DFa Variance F P-value
Gene 1,273,829,72 26,371 48,3 130,03 < 0,00001
Age 284,86 1 284,86 766,82 < 0,00001
Clinical status 1302,22 2 651,11 1752,7 < 0,00001
Gender 33,19 1 33,19 89,34 < 0,00001
Leucocyte 318,45 1 318,45 857,23 < 0,00001
Residualb 146,951,38 395,574 0,37 – –
Total 1,422,740,94 421,951 3,37 – –
aDegree of freedom
bThe residual corresponds to the variance that was not explained by
the model
Table 3 Multi-way ANOVA of gene expression levels in blood
samples from MM and CM patients
Factor Sum of square DFa Variance F P-value
Gene 1,149,572,54 24,575 46,78 135,88 < 0,00001
Age 330,03 1 330,03 958,71 < 0,00001
Cerebral malaria 1169,2 1 1169,2 3396,38 < 0,00001
Gender 152,75 1 152,75 443,71 < 0,00001
Leucocyte 147,91 1 147,91 429,65 < 0,00001
Residualb 126,902,45 368,636 0,34 – –
Total 1,278,274,87 393,215 3,25 – –
aDegree of freedom
bThe residual corresponds to the variance that was not explained by
the model
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after correcting for multiple tests, no significantly
expressed genes remained. Figure 2 shows the unsuper-
vised hierarchical clustering based on the 14 genes.
We further performed a multi-way ANOVA to take
into account the effect of potential confounding factors.
First, we included MM, NCM, and CM patients, and
then we considered only MM and CM patients. Tables 2
and 3 show the result of the global ANOVA; gene factor,
gender, age, leukocyte count, and clinical status were
sources of variation. Furthermore, we performed an
ANOVA for each gene, taking into account the effect of
confounding factors. The analysis of the three patient
groups identified 503 probes corresponding to 443 genes
whose expression levels differed significantly, with an
FDR of 10% (Additional file 1: Table S1). For those
genes, the median of the variance explained by clinical
status was 19.6% (minimum = 4.7% and maximum =
36.2%). On the basis of the expression of those genes,
the CM patients differed in their expression compared
to MM and NCM patients (Fig. 3). We further investi-
gated the pattern of gene expression in MM and CM pa-
tients. After applying an FDR of 10%, we identified 1060
probes corresponding to 842 genes, the expression of
which differed in MM and CM (Additional file 1: Table
S1). For those genes, the median of the variance
explained by CM factor was 40.3% (minimum = 8.7%
and maximum = 72.4%). The unsupervised hierarchical
clustering of CM-informative genes is presented in Fig. 4.
On this basis, the CM patients were clustered together,
suggesting that gene expression profiles were well dis-
criminated between cerebral and mild malaria patients.
This was further supported by another analysis based on
the SVM method. We used a ‘1-out-iterative cross-
validation’ testing procedure. Iteratively, 1 out of the 12
samples was removed from the group and was classified
based on the correlation between its expression profile
and the median profile of samples from CM and MM
patients. Accordingly, we correctly classified five out of
six cerebral malaria patients and six of six mild malaria
patients (P = 0.015).
We further analysed the expression of eight selected
genes by RT-qPCR to confirm their gene expression
patterns. The level of gene expression measured with
the microarray method was correlated with that mea-
sured with the qPCR method for the studied genes
(Additional file 2: Figure S1). The correlation coefficient
Fig. 3 Hierarchical clustering of cerebral malaria (CM), severe non-cerebral (NCM) and mild malaria (MM) patients on the basis of differentially
expressed genes. A multi-way ANOVA, which took into account confounding factors, led to the identification of genes whose expressions differed
in CM, NCM, and MM patients after applying an FDR of 10%. Each column represents a patient. Genes that were down- and up-regulated in CM
patients are shown in cluster A and cluster B, respectively. The list of those genes is shown in Additional file 1: Table S1
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ranged from 0.69 to 0.94 (P < 0.02). Also, the qPCR re-
sults confirmed the microarray results.
Functional enrichment
When analysing the genes showing a differential expres-
sions in CM, NCM, and MM patients, there was no sig-
nificant functional enrichment on the basis of the Kyoto
Encyclopaedia of Genes and Genomes (KEGG) pathways.
Nevertheless, the analysis of molecular immune signatures
from the Molecular Signatures Database (MSigDB)
showed an over-representation of genes regulated in acti-
vated CD4 lymphocytes, CD8 lymphocytes, B lympho-
cytes, NK lymphocytes, macrophages, monocytes, and
dendritic cells (Table 4 and Additional file 3: Table S2).
Using the differentially expressed genes in the CM and
MM groups, we found very similar results (Table 5 and
Additional file 3: Table S2).
The products of those genes, whose expressions dif-
fered in the MM and SM groups based on the multi-
way ANOVA, were further mapped onto a human
protein-protein network, leading to subnetworks.
Figure 5 shows the protein-protein interaction (PPI)
network of significantly regulated genes in MM, CM,
and NCM patients, whereas Fig. 6 shows the PPI net-
work of significantly regulated genes in MM and CM
patients. The PPI network of genes regulated in MM,
CM, and NCM patients was composed of 810 nodes in-
cluding 322 seed nodes and 2574 edges, whereas the
PPI network of genes regulated in MM and CM pa-
tients was composed of 1479 nodes including 629 seed
nodes and 6479 edges. Additional file 4: Table S3 shows
the list of the nodes and their degree and their be-
tweenness centrality measures. When comparing the
two PPI networks for the nodes with the highest de-
grees, the following nodes belong to the best 10 nodes
in both networks: UBC, GSK3B, EEF1A1, RELA, APP,
and ELAVL1. Noticeably, GSK3B is involved in KEGG
pathways, such as TCR- and BCR-signalling and Alz-
heimer’s disease pathways. RELA is involved in TCR-,
BCR-, TLR-, and RIG-I-like receptor-signalling path-
ways, whereas APP is involved in Alzheimer’s disease
pathway. The two PPI networks were significantly
enriched for more than 100 Reactome and KEGG path-
ways (Additional file 5: Table S4). Tables 6 and 7 shows
a selection of pathways of interest, such as Alzheimer’s
disease, BCR-, TCR-, TLR-, cytokine-, FcεRI-, FCGR-,
Fig. 4 Hierarchical clustering of cerebral malaria (CM) and mild malaria (MM) patients on the basis of differentially expressed genes. A multi-way
ANOVA was performed to selectively identify differentially expressed genes in CM and MM patients after an FDR of 10%. Each column represents
a patient. Genes that were down- and up-regulated in CM patients are shown in cluster A and cluster B, respectively. The list of those genes is
shown in Additional file 1: Table S1
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RIG-I-like receptor-signalling pathways, and natural
killer cell mediated cytotoxicity.
Discussion
In this study, we investigated blood gene expression pat-
terns in patients with MM, severe NCM, or CM. We
identified a molecular signature associated with CM in
humans, which was enriched with pathways involved in
the activation of immune cells, such as monocytes, mac-
rophages, B and T lymphocytes, and natural killer cells.
We performed microarray experiments and analysed
the data using one-way statistical analyses. We identified
genes whose expression levels differed at a nominal P
value level under 0.001. However, no significant genes
remained after multiple test corrections. Since several
confounding factors may diminish the power of the
analysis, we assessed the effects of age, gender, and
leucocyte count on gene expression, and further took
their effects into account. Also, we identified 443 genes,
the expressions of which differed in MM, severe NCM,
and CM patients. This molecular signature mainly
discriminated the CM patients from the others; in the
same way, severe anaemia and CM patients were
reported to differ in their transcriptional and im-
munological profiles [24, 25]. Furthermore, we focused
on CM patients in comparison to MM patients, and
identified 842 genes, the expressions of which differed in
MM and CM patients. These results are in line with
those obtained in blood and brain samples from CM
mice [7, 26], and support the existence of blood gene ex-
pression profiles associated with CM. Furthermore, they
suggest that gene expression profiles might be detected
before the occurrence of CM in humans. Such predictive
profiles have been identified in mice with CM [7].
Functional enrichment analyses identified several path-
ways that may be altered by the regulation of gene ex-
pression in CM patients. Interestingly, we detected an
enrichment of a neurodegenerative disease signature, as
previously reported [13, 24], and we identified APP,
which is involved in Alzheimer’s disease [27], as a node
with a high number of interactions within the PPI net-
work associated with CM. This suggests that some
Table 4 MsigDB molecular signatures enrichment analysis for genes differentially expressed between MM, CM and NCM patients
IDa Description P value FDR
GSE29617 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from TIV influenza vaccine
pre-vaccination versus those at day 3 post-vaccination.
5,16E-07 9,85E-04
GSE17721 Genes up-regulated in comparison of dendritic cells (DC) stimulated with poly(I:C) (TLR3 agonist) at 1 h versus DC
cells stimulated with Pam3Csk4 (TLR1/2 agonist) at 1 h.
9,56E-06 4,56E-03
GSE3337 Genes down-regulated in comparison of untreated CD8+ dendritic cells (DC) at 16 h versus those treated with
IFNG [GeneID = 31,658] at 16 h.
2,75E-05 8,76E-03
GSE17721 Genes up-regulated in comparison of control dendritic cells (DC) at 4 h versus those stimulated with CpG DNA
(TLR9 agonist) at 4 h.
5,22E-05 1,11E-02
GSE17721 Genes up-regulated in comparison of control dendritic cells (DC) at 2 h versus those stimulated with LPS
(TLR4 agonist) at 2 h.
8,88E-05 1,54E-02
GSE19825 Genes down-regulated in comparison of naive CD8 T cells versus effector CD8 T cells. 1,34E-04 1,82E-02
GSE14308 Genes up-regulated in comparison of Th2 cells versus naive CD4 [GeneID = 620] T cells. 1,32E-04 1,94E-02
GSE17721 Genes up-regulated in comparison of dendritic cells (DC) stimulated with Gardiquimod (TLR7 agonist) at 0.5 h versus
those stimulated with Gardiquimod (TLR7 agonist) at 8 h.
1,62E-04 2,07E-02
GSE9988 Genes down-regulated in comparison of monocytes treated with 5000 ng/ml LPS (TLR4 agonist) versus monocytes
treated with control IgG.
2,38E-04 2,39E-02
GSE29617 Genes up-regulated in comparison of peripheral blood mononuclear cells (PBMC) from TIV influenza vaccinee before
vaccination versus that after the vaccination.
2,70E-04 2,57E-02
GSE36476 Genes down-regulated in comparison of memory CD4 [GeneID = 920] T cells from young donors treated with TSST at
40 h versus those from old donors treated with TSST at 40 h.
4,19E-04 3,48E-02
GSE17721 Genes up-regulated in comparison of control dendritic cells (DC) at 24 h versus those stimulated with Pam3Csk4
(TLR1/2 agonist) at 24 h.
5,45E-04 4,00E-02
GSE9988 Genes down-regulated in comparison of monocytes treated with anti-TREM1 [GeneID = 54,210] and 5000 ng/ml LPS
(TLR4 agonist) versus monocytes treated with control IgG.
5,41E-04 4,14E-02
GSE17721 Genes up-regulated in comparison of control dendritic cells (DC) at 12 h versus those stimulated with LPS
(TLR4 agonist) at 12 h.
6,79E-04 4,32E-02
GSE25087 Genes down-regulated in comparison of fetal regulatory T cell (Treg) versus fetal conventional T cells. 2,69E-03 8,85E-02
GSE24634 Genes up-regulated in comparison of naive T cells at day 0 versus CD25+ regulatory T cell (Treg) treated with IL4
[GeneID = 3565] at day 7.
3,16E-03 9,73E-02
aMsigDB molecular signatures have been selected among those that were significant
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biological pathways are involved in both CM and neuro-
degenerative diseases. Nevertheless, most of the identi-
fied pathways were immune pathways. Strikingly, the
functional enrichment of molecular signatures in specific
cells using MSigDB data was consistent with the func-
tional enrichment of PPI networks, which were con-
structed on the basis of regulated genes. These included
BCR-, TCR-, TLR-, FcεRI-, FcγR-, and RIG-I-like recep-
tor- signalling pathways, and natural killer cell mediated
cytotoxicity pathway. Noticeably, BCR- and TCR- signal-
ling pathways were also associated with CM, on the basis
of the brain transcriptional analysis of CM-resistant and
CM-susceptible mice [7], whereas the TLR-signalling
pathway was associated with SM in Mali [12]. Moreover,
there was an over-representation of MSigDB molecular
signatures of activated monocytes, dendritic cells, mac-
rophages, NK cells, B lymphocytes, CD8 T lymphocytes,
and CD4 T lymphocytes, including Th1, Th2, and T
regulatory cells. These findings are consistent with the
involvement of those immune cells in malaria pathogen-
esis. IgG produced by B lymphocytes activate effector
cells through FcγRIIA to kill the parasites [28]. Mono-
cytes and macrophages activated through TLR and Th1
effector lymphocytes produce pro-inflammatory cyto-
kines that are thought to be involved in both parasite
clearance and immunopathology [29]. Pro-inflammatory
cytokines, such as TNF and IFNγ, increase the expres-
sion of adhesion molecules on endothelial cells, such as
ICAM1, leading to the binding of infected red blood
cells on endothelial cells [30–32]. It has been suggested
that histamine-secreting basophils activated by IgE
through FcεRI increase vaso-permeability and the over-
expression of ICAM1 on endothelial cells, suggesting
that Th2 lymphocytes promoting the production of IgE
Table 5 MsigDB molecular signatures enrichment analysis for genes differentially expressed between MM and CM patients
IDa Description P value FDR
GSE14308 Genes up-regulated in comparison of Th2 cells versus naive CD4 [GeneID = 620] T cells. 2,98E-07 1,42E-04
GSE17721 Genes up-regulated in comparison of control dendritic cells (DC) at 12 h versus those stimulated with LPS
(TLR4 agonist) at 12 h.
7,81E-06 1,07E-03
GSE14769 Genes up-regulated in comparison of unstimulated macrophage cells versus macrophage cells stimulated with
LPS (TLR4 agonist) for 120 min.
7,52E-06 1,10E-03
GSE14000 Genes up-regulated in comparison of dendritic cells (DC) before and 4 h after LPS (TLR4 agonist) stimulation. 1,65E-05 1,75E-03
GSE11864 Genes up-regulated in comparison of untreated macrophages versus those cultured with M-CSF [GeneID = 1435]
and IFNG [GeneID = 3458].
1,93E-05 1,76E-03
GSE18791 Genes up-regulated in comparison of control conventional dendritic cells (cDC) at 10 h versus cDCs infected with
Newcastle disease virus (NDV) at 10 h.
1,04E-04 5,50E-03
GSE17974 Genes up-regulated in comparison of CD4 [GeneID = 920] T cells treated with IL4 [GeneID = 3565] and anti-IL12
at 0.5 h versus those at 72 h.
4,14E-04 1,47E-02
GSE15930 Genes down-regulated in comparison of CD8 T cells at 0 h versus those at 24 h after stimulation with IL12 . 5,62E-04 1,79E-02
GSE22886 Genes up-regulated in comparison of naive CD4 [GeneID = 920] T cells versus stimulated CD4 [GeneID = 920]
Th2 cells at 12 h.
7,93E-04 2,13E-02
GSE25087 Genes down-regulated in comparison of fetal regulatory T cell (Treg) versus fetal conventional T cells. 1,45E-03 2,75E-02
GSE24634 Genes up-regulated in comparison of CD25+ T cells treated with IL4 [GeneID = 3565] versus CD25- T cells
treated with IL4 [GeneID = 3565] at day 5.
1,69E-03 3,11E-02
GSE9988 Genes down-regulated in comparison of monocytes treated with anti-TREM1 [GeneID = 54,210] and
5000 ng/ml LPS (TLR4 agonist) versus monocytes treated with control IgG.
2,55E-03 3,77E-02
GSE14308 Genes down-regulated in comparison of Th1 cells versus induced regulatory T cell (Treg). 3,90E-03 4,81E-02
GSE13229 Genes down-regulated in comparison of mature NK cells versus intermediate mature NK cells. 4,43E-03 5,26E-02
GSE13306 Genes up-regulated in comparison of CD4 [GeneID = 920] T cells activated with lamina propria
dendritic cells versus regulatory T cell (Treg).
7,03E-03 7,10E-02
GSE26495 Genes up-regulated in comparison of naive CD8 T cells versus PD-1 low CD8 T cells. 8,22E-03 7,74E-02
GSE17580 Genes down-regulated in comparison of regulatory T cell (Treg) from uninfected mice versus regulatory
T cell (Treg) from mice infected with S. mansoni.
8,92E-03 7,85E-02
GSE14308 Genes up-regulated in comparison of Th2 cells versus natural regulatory T cell (Treg). 8,77E-03 7,86E-02
GSE22886 Genes up-regulated in comparison of naive CD4 [GeneID = 920] T cells versus stimulated CD4 [GeneID = 920]
Th1 cells at 12 h.
1,04E-02 8,67E-02
GSE9650 Genes up-regulated in comparison of effector CD8 T cells versus exhausted CD8 T cells. 1,64E-05 1,84E-03
GSE25087 Genes down-regulated in comparison of fetal regulatory T cell (Treg) versus fetal conventional T cells. 1,45E-03 2,75E-02
aMsigDB molecular signatures have been selected among those that were significant
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play a role in malaria [33]. Besides, IFNγ that is pro-
duced by Th1 lymphocytes induces the expression of
CXCL10 by endothelial cells, leading to an increased
adhesion of T lymphocytes [31]. CD8 T lymphocytes
recognize plasmodial antigens presented by the MHC
class I of the endothelial cells, leading to the death of
endothelial cells, to the disruption of the blood-brain
barrier, and, potentially, cerebral haemorrhages, as
shown in mice with CM [34–36]. T regulatory lympho-
cytes are thought to be the key actors of Th1 effector
lymphocyte regulation in malarial infection, and an ex-
cessive T regulatory induction, which might lead to
high parasitaemia at the early stage of infection, might
benefit the host at later stages by preventing an exces-
sive Th1 effector lymphocyte response [37], including
an excessive production of pro-inflammatory cyto-
kines. In this way, IL18R and IL1RN that encode for
receptors of pro-inflammatory cytokines were up-
regulated in malaria patients in Benin [38] and in CM
patients in our study population, whereas IL18R was
up-regulated in blood from CM mice [26]. Interest-
ingly, IL18 produced by myeloid cells is required for
an optimal activation of NK cells upon contact with in-
fected red blood cells [39]. The role of NK cells re-
mains, nevertheless, to be clarified. Although NK cells
control malaria infection by killing the parasite and by
early producing IFNγ, NK cells may produce inflam-
matory cytokines in brain microvessels and may amp-
lify the sequestration of infected red blood cells and
CD8 T lymphocytes and the disruption of the blood-
brain barrier [34, 40]. However, patients with SM were
reported to have a lower NK cell cytotoxicity activity
than patients with MM, suggesting a protective role
against SM [41]. In addition, the RIG-I-like receptor-
signalling pathway, which was enriched in genes regu-
lated in CM patients in our study, was shown to be an
important pathway to activate the NK cells and kill the
parasite [41].
Fig. 5 Protein-protein interaction (PPI) network of the differentially expressed genes in MM, CM, and CM patients. The size of the nodes is based
on their degree centrality, whereas the intensity of their colour reflects their betweenness centrality
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Although our results are in line with published results
and propose signal transduction pathways involved in
the pathology, they will not provide definitive insights
into molecular and cellular mechanisms of cerebral
malaria pathogenesis. Also, it is important to point out
the limits of the study. First, transcriptional profiling
may be influenced by the differences in cellular com-
position in PBMC. Furthermore, looking for gene ex-
pression profiles in well defined cell types will likely
provide specific transcriptional profiles associated with
CM. Using single-cell RNA sequencing approach would
be a promising approach to reach this objective [42].
Second, the sample size of our study is small, and repli-
cation studies should be performed. Third, studying
blood cells gives an incomplete view of CM pathogen-
esis mechanisms, because other cells and tissues are in-
volved. In particular, brain microvascular endothelial
cells play a central role in CM [30, 31, 43, 44]. How-
ever, obtaining brain endothelium in humans is very
difficult, and in vitro and in vivo models are rather used
to investigate the role of such cells in CM. Fourth, it is
not possible to determine the molecular factors causing
CM on the basis of our results, because gene expression
levels were measured at the time of malaria attacks.
Measuring gene expression levels in patients before CM
attacks is very challenging. Interestingly, such studies
that have been performed in mice infected by Plasmo-
dium berghei ANKA led to identify predictive profiles
before the onset of cerebral malaria [7]. This suggests
that new candidate causal factors can be identified in
this in vivo model and can be tested using gene target-
ing approach in mice infected by Plasmodium berghei
ANKA. It should be stressed, however, that some au-
thors wrote that the murine model is not relevant for
the human disease, whereas other authors pointed out
that there are many common features between mouse
pathology and human pathology [30, 31, 44, 45]. In par-
ticular, White et al. maintained that mice with CM
show no or little parasite sequestration within the
brain, and that human CM mainly results from parasite
sequestration and brain microvessels obstruction [46].
Interestingly, Strangward et al. recently showed that the
Fig. 6 Protein-protein interaction (PPI) network of the differentially expressed genes in MM and CM patients. The size of the nodes is based on
their degree centrality, whereas the intensity of their colour reflects their betweenness centrality
Thiam et al. BMC Medical Genomics          (2019) 12:148 Page 11 of 15
accumulation of parasitized red blood cells in brain
microvessels was a feature of mouse CM that was not
observed during uncomplicated malaria attacks [47]. It
is likely, however, that a single mouse model does not
fully reflect the biological mechanisms underlying CM
in humans. Noticeably, there is accumulating evidence
of the critical role of CD8+ T lymphocytes in mouse
CM, whereas there is little evidence of high numbers of
CD8+ T lymphocytes in human brain microvessels dur-
ing CM attacks. Brain endothelial cells have been
shown to crosspresent Plasmodium berghei ANKA anti-
gens to mouse CD8+ T lymphocytes [34, 35], whereas
it has not been reported in humans. Nevertheless, a hu-
man brain endothelial cell line has been shown to
Table 6 Reactome and KEGG pathways enrichment analysis for genes differentially expressed between MM and CM patients
Pathways Reactome databasea Total Expected Hits P value FDR
Immune System 1140 70,7 136 4,47E-16 6,27E-13
Signaling by the B Cell Receptor (BCR) 199 12,4 44 4,15E-14 1,45E-11
Constitutive Signaling by NOTCH1 PEST Domain Mutants 59 3,67 22 1,75E-12 3,51E-10
Downstream Signaling Events Of B Cell Receptor (BCR) 173 10,8 38 3,14E-12 5,50E-10
Activation of NF-kappaB in B Cells 66 4,1 22 2,37E-11 3,69E-09
Signaling by NOTCH1 74 4,6 23 4,21E-11 3,69E-09
Signaling by ERBB4 152 9,45 33 1,26E-10 9,31E-09
Cytokine Signaling in Immune system 286 17,8 44 1,24E-08 4,98E-07
ER-Phagosome pathway 63 3,92 17 1,59E-07 4,04E-06
TCR signaling 65 4,04 17 2,60E-07 5,89E-06
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 67 4,16 17 4,19E-07 8,51E-06
Cross-presentation of soluble exogenous antigens 48 2,98 14 7,08E-07 1,34E-05
TRAF6 Mediated Induction of proinflammatory cytokines 62 3,85 16 7,18E-07 1,34E-05
Fcgamma receptor (FCGR) dependent phagocytosis 86 5,35 19 8,95E-07 1,65E-05
Platelet activation signaling and aggregation 220 13,7 33 1,64E-06 2.84E-05
DAP12 signaling 164 10,2 27 2,47E-06 4,23E-05
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 76 4,72 17 2,82E-06 4,76E-05
Toll Like Receptor 7/8 (TLR7/8) Cascade 77 4,79 17 3,42E-06 5,51E-05
TRIF-mediated TLR3/TLR4 signaling 87 5,41 18 4,73E-06 7,21E-05
Toll Like Receptor 9 (TLR9) Cascade 79 4,91 17 4,96E-06 7,30E-05
MyD88-independent cascade 88 5,47 18 5,61E-06 8,03E-05
Toll Like Receptor 10 (TLR10) Cascade 74 4,6 16 8,84E-06 1,15E-04
Toll Like Receptor 5 (TLR5) Cascade 74 4,6 16 8,84E-06 1,15E-04
Pathways from KEGG databasea Total Expected Hits P value FDR
Neurotrophin signaling pathway 123 8,75 31 1,98E-10 7,16E-09
Bacterial invasion of epithelial cells 56 3,98 20 4,68E-10 1,45E-08
Notch signaling pathway 47 3,34 18 9,49E-10 2,06E-08
T cell receptor signaling pathway 98 6,97 25 9,42E-09 1,57E-07
Endocytosis 101 7,19 23 3,59E-07 3,71E-06
B cell receptor signaling pathway 75 5,34 19 6,75E-07 6,1E-06
RIG-I-like receptor signaling pathway 49 3,49 12 0,000115 0,000653
Leukocyte transendothelial migration 108 7,68 19 1,75E-04 8,61E-04
Epithelial cell signaling in Helicobacter pylori infection 37 2,63 10 1,79E-04 8,61E-04
Toll-like receptor signaling pathway 97 6,9 16 1,18E-03 4,64E-03
Fc epsilon RI signaling pathway 75 5,34 12 6,10E-03 2,1E-02
Alzheimer’s disease 49 3,49 8 2,08E-02 6,28E-02
aPathways have selected among those that were significant
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phagocytose P. falciparum merozoites, suggesting that
human endothelial cells may crosspresent plasmodial
antigens to human CD8+ T lymphocytes [35]. Also, we
consider that the mouse CM model can provide new
functional hypotheses that should be tested in humans.
Conclusions
We identified genes expression profiles that discrimi-
nated between CM and MM patients on the one hand,
and immune molecular pathways associated with CM on
the other hand. Our results are in line with the involve-
ment of monocytes, macrophages, dendritic cells, and B
and T lymphocytes, and NK cells in malaria pathogen-
esis. Further studies are required to confirm the molecu-
lar signatures of CM, and to identify those of severe
NCM. In addition, further comparisons of severe malaria
patient gene expression levels to that of mild malaria
patients may reveal a molecular signature common to
severe malaria phenotypes. Finally, genetic variation that
influences gene expression in patients with clinical mal-
aria may modulate the immunopathological response.
We think that looking for such regulatory variants will
help to better uncover the genetic basis of severe forms
of malaria in African populations.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12920-019-0599-z.
Additional file 1: Table S1. Differentially expressed genes in MM vs CM
vs NCM and MM vs CM analyses. Results of the Welch t test, one-way
ANOVA analyses, and multi-way ANOVA analyses are shown.
Table 7 Reactome and KEGG pathways enrichment analysis for genes differentially expressed between MM, CM and NCM patients
Pathways from Reactome databasea Total Expected Hits P value FDR
Activation of NF-kappaB in B Cells 66 7.06 31 7,21E-14 9,19E-12
Signaling by the B Cell Receptor (BCR) 199 21.3 58 2,40E-13 2,59E-11
Adaptive Immune System 654 69.9 128 7,82E-13 6,57E-11
Downstream Signaling Events Of B Cell Receptor 173 18.5 51 4,45E-12 2,83E-10
Signaling by Interleukins 116 12.4 39 1,92E-11 1,03E-09
Signalling by NGF 290 31 67 3,70E-10 1,18E-08
NOTCH1 Intracellular Domain Regulates Transcription 50 5.35 21 1,02E-08 2,16E-07
ER-Phagosome pathway 63 6.74 23 4,85E-08 8,09E-07
Platelet activation signaling and aggregation 220 23.5 50 1,23E-07 1,92E-06
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 76 8.13 25 1,37E-07 2,08E-06
Toll Like Receptor 7/8 (TLR7/8) Cascade 77 8.23 25 1,82E-07 2,69E-06
MyD88-independent cascade 88 9.41 27 2,19E-07 3,17E-06
Toll Like Receptor 3 (TLR3) Cascade 88 9.41 27 2,19E-07 3,17E-06
Activated TLR4 signalling 100 10.7 29 3,02E-07 4,22E-06
Fcgamma receptor (FCGR) dependent phagocytosis 86 9.2 26 5,07E-07 6,71E-06
Toll Like Receptor 4 (TLR4) Cascade 103 11 29 6,01E-07 7,80E-06
Pathways from KEGG databasea Total Expected Hits P value FDR
T cell receptor signaling pathway 98 11,1 35 1,15E-10 5E-09
Bacterial invasion of epithelial cells 56 6,32 24 1,47E-09 4,55E-08
B cell receptor signaling pathway 75 8,46 25 2,66E-07 2,8E-06
Fc gamma R-mediated phagocytosis 97 10,9 28 1,46E-06 1,22E-05
Endocytosis 101 11,4 27 1,11E-05 6,88E-05
TGF-beta signaling pathway 84 9,48 20 8,03E-04 3,71E-03
Fc epsilon RI signaling pathway 75 8,46 18 1,31E-03 5,48E-03
Toll-like receptor signaling pathway 97 10,9 21 2,19E-03 8,64E-03
RIG-I-like receptor signaling pathway 49 5,53 12 6,85E-03 2,25E-02
Alzheimer’s disease 49 5,53 11 1,82E-02 5,41E-02
Natural killer cell mediated cytotoxicity 138 15,6 23 3,41E-02 9,37E-02
aPathways have selected among those that were significant
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Additional file 2: Figure S1. The correlation between gene expression
levels measured by qPCR and those measured by microarray technology
for CM and MM patients. Eight genes were selected. The qPCR data were
analysed by the 2-deltadeltaC(t) method with GAPDH as a control gene.
Both the qPCR and the microarray data were normalized on the basis of
the values obtained with a reference sample.
Additional file 3: Table S2. Enriched MSigDB signatures for MM vs CM
vs NCM and MM vs CM analyses.
Additional file 4: Table S3. Protein-protein interaction (PPI) network
nodes: degree and betweenness centrality for MM vs CM vs NCM and
MM vs CM analyses.
Additional file 5: Table S4. Enriched Reactome and KEGG pathways for
MM vs CM vs NCM and MM vs CM analyses.
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